Coronavirus Update: Moderna’s Omicron Vaccine Study Successful, But Data Draw Skepticism

 
• By Alaric DeArment

AstraZeneca also published efficacy data for Evusheld in patients with mild-to-moderate COVID-19, while Pfizer is investing $120m in expanding its Paxlovid manufacturing footprint in Michigan.

Moderna announced results from the Phase II/III study of its mRNA-1273.214 vaccine candidate • Source: Shutterstock

More from COVID-19

More from Scrip